Isis Pharmaceuticals Inc Sells 3,150 Shares of Regulus Therapeutics Stock (RGLS)
Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc sold 3,150 shares of the stock on the open market in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $7.08, for a total value of $22,302.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at FBR Capital Markets raised their price target on shares of Regulus Therapeutics from $14.00 to $15.00 in a research note on Thursday. They now have an “outperform” rating on the stock. Analysts at Brinson Patrick initiated coverage on shares of Regulus Therapeutics in a research note on Tuesday, May 13th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Regulus Therapeutics presently has an average rating of “Buy” and a consensus price target of $16.20.
Shares of Regulus Therapeutics (NASDAQ:RGLS) traded up 1.34% during mid-day trading on Friday, hitting $6.81. The stock had a trading volume of 43,818 shares. Regulus Therapeutics has a 52 week low of $5.40 and a 52 week high of $11.88. The stock’s 50-day moving average is $7. and its 200-day moving average is $7.98. The company’s market cap is $295.3 million.
Regulus Therapeutics (NASDAQ:RGLS) last released its earnings data on Wednesday, August 6th. The company reported ($0.29) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.19) by $0.10. On average, analysts predict that Regulus Therapeutics will post $-0.89 earnings per share for the current fiscal year.
Regulus Therapeutics Inc, is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.